Summary & Overview
HCPCS Q5122: Injection, pegfilgrastim-apgf (Nyvepria), 0.5 mg
HCPCS Level II code Q5122 designates the biosimilar pegfilgrastim-apgf (Nyvepria) in a 0.5 mg injection formulation. Pegfilgrastim biosimilars are clinically important for reducing febrile neutropenia risk in patients undergoing myelosuppressive chemotherapy, and coding clarity affects access and billing consistency across outpatient and hospital settings. Nationally, clear use of biosimilar HCPCS codes supports accurate reimbursement, utilization tracking, and biosimilar adoption.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of payer coverage patterns and coding considerations for Q5122, where available, and highlights clinical context for pegfilgrastim biosimilars.
Readers will learn: the clinical purpose of the code, typical sites of service for administration, and which major national payers are relevant for coverage considerations. The report summarizes available benchmarks and policy updates that affect billing and utilization of pegfilgrastim biosimilars. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code Q5122 represents Injection, pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg. This code is used for billing administration of the biosimilar pegfilgrastim-apgf formulation, a granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy.
Service Type: Injection / Biosimilar biologic administration
Typical Site of Service: Outpatient infusion clinic, physician office, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with stage IIIB non-small cell lung cancer receives cytotoxic chemotherapy and is at risk for chemotherapy-induced neutropenia. The oncology clinic administers the biosimilar long-acting granulocyte colony-stimulating factor Q5122 (pegfilgrastim-apgf, nyvepria) 0.5 mg by subcutaneous injection 24–72 hours after chemotherapy or as indicated by the treating oncologist. The workflow includes verification of chemotherapy cycle dates, review of recent complete blood count (CBC) values, allergy check, informed consent, and documentation of dose, lot number, and injection site. The medication is prepared by an authorized pharmacist or trained nurse, delivered via prefilled syringe at the clinic or administered by a home health nurse under an ordered protocol. Billing uses the HCPCS Level II code Q5122 with appropriate modifier(s) to indicate payment circumstances or provider status. Clinical monitoring includes observation for immediate injection reactions for 15–30 minutes and scheduling of follow-up CBC and next-cycle planning for continued prophylaxis of febrile neutropenia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug/biological not administered; single-dose container discarded | Use when the drug was not given and no part of the single-use vial/syringe was administered. |